$ATNM

Actinium Pharmaceuticals (ATNM) has begun enrolling patients in the RADIANZ clinical trial for ATNM-400, a HER3-targeting radiotherapy. The study aims to expand ATNM-400's potential beyond prostate cancer to other solid tumors. Initial data in prostate cancer showed tumor uptake and no dose-limiting toxicities. The company plans to present additional breast cancer data at the San Antonio Breast Cancer Symposium.

Actinium Pharmaceuticals (ATNM) announced three abstracts for ASH 2026, highlighting Iomab-ACT's potential in CAR T-cell therapy and sickle cell disease. The studies explore Iomab-ACT as a conditioning agent before cellular therapies, reducing reliance on chemotherapy. According to the company, the results support Iomab-ACT's development as a universal targeted conditioning regimen.

Actinium Pharmaceuticals (ATNM) announced long-term safety results of Actimab-A combined with CLAG-M for relapsed/refractory AML at ASH 2026. The study showed potential for bone marrow recovery and addressed kidney/liver toxicities. Prior data showed 1- and 2-year survival rates of 59% and 32% in venetoclax-failed patients, and 51% and 19% in TP53-mutated AML patients. Actinium aims to develop Actimab-A as a mutation-agnostic AML treatment.

Actinium Pharmaceuticals (ATNM) announced that its abstract on ATNM-400, a targeted alpha therapy for breast cancer, was accepted for presentation at the 2026 San Antonio Breast Cancer Symposium. The study highlights ATNM-400's efficacy across therapy-resistant breast cancer subtypes, reinforcing its potential as a pan-tumor treatment. The company is also developing ATNM-400 for prostate, lung, colorectal, and ovarian cancers.

Biohaven (BHVN) +31% after FDA accepted resubmitted drug application for spinocerebellar ataxia. Korro Bio (KRRO) +25% on positive preclinical results for AATD treatment. Actinium (ATNM) +18% with initial Phase 1 data for prostate cancer radiotherapy. Vicore (VCRE) +16% after passing IPF trial futility analysis.

Actinium Pharmaceuticals (ATNM) reported that its experimental treatment, ATNM-400, showed significant tumor growth inhibition in lung, colorectal, and ovarian cancer models. The drug demonstrated activity across various cancer types, including treatment-resistant cases, supporting its potential as a pan-tumor therapy. The company plans to advance ATNM-400 across multiple solid tumor indications, with ongoing clinical development in prostate cancer.

Biotech stocks rallied on Monday, with Silence Therapeutics (SLN) up 125% after a $1.3B acquisition by Merck, SCWorx (WORX) up 105% on a new healthcare deal, and Disc Medicine (IRON) up 41% on positive trial results. Actinium (ATNM) and Evaxion (EVAX) also saw gains on clinical updates.

Actinium Pharmaceuticals will present Phase 1 data for ATNM-400 in metastatic prostate cancer and preclinical results in lung cancer at EANM 2026. ATNM-400 targets HER3, offering potential across multiple solid tumors. The company focuses on developing targeted radiotherapies for cancer treatment.

Actinium Pharmaceuticals presented preclinical data showing ATNM-400, its targeted radiotherapy, demonstrated antitumor activity in lung, colorectal, and ovarian cancer models, including resistant tumors. The findings support ATNM-400's potential as a monotherapy and in combination with existing treatments across multiple cancer indications.

Actinium Pharmaceuticals, Inc. (ATNM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer NEW YORK, October 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (“Actinium” or the “Company”), a pioneer in the develo